Total Payments
$45,038
2024 Payments
$2,451
Companies
6
Transactions
54
Medicare Patients
45,782
Medicare Billing
$39.5M
Payment Breakdown by Category
Research$35,912 (79.7%)
Other$6,341 (14.1%)
Consulting$2,382 (5.3%)
Food & Beverage$385.71 (0.9%)
Education$17.19 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $35,912 | 33 | 79.7% |
| Current or prospective ownership or investment interest | $6,326 | 6 | 14.0% |
| Consulting Fee | $2,382 | 1 | 5.3% |
| Food and Beverage | $385.71 | 12 | 0.9% |
| Education | $17.19 | 1 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14.54 | 1 | 0.0% |
Payments by Type
Research
$35,912
25 transactions
General
$9,126
21 transactions
Ownership
$0
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alcon Research Ltd | $30,887 | 24 | $0 (2017) |
| US Retina LLC | $6,326 | 14 | $0 (2024) |
| Alimera Sciences, Inc. | $5,236 | 4 | $0 (2019) |
| Astellas Pharma US Inc | $2,488 | 6 | $0 (2024) |
| Notal Vision, Inc. | $83.18 | 5 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $17.19 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,451 | 6 | Astellas Pharma US Inc ($2,382) |
| 2023 | $17.19 | 2 | Apellis Pharmaceuticals, Inc. ($17.19) |
| 2022 | $2,668 | 4 | US Retina LLC ($2,653) |
| 2021 | $1,669 | 3 | US Retina LLC ($1,669) |
| 2020 | $866.73 | 2 | US Retina LLC ($866.73) |
| 2019 | $1,176 | 3 | US Retina LLC ($1,137) |
| 2018 | $254.47 | 7 | Alimera Sciences, Inc. ($172.03) |
| 2017 | $35,936 | 27 | Alcon Research Ltd ($30,887) |
All Payment Transactions
54 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Notal Vision, Inc. | Foresee Home (Device) | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: Ophthalmology | ||||||
| 08/20/2024 | Notal Vision, Inc. | Foresee Home (Device) | Food and Beverage | In-kind items and services | $16.49 | General |
| Category: Ophthalmology | ||||||
| 07/15/2024 | Notal Vision, Inc. | Foresee Home (Device) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: Ophthalmology | ||||||
| 06/18/2024 | Notal Vision, Inc. | Foresee Home (Device) | Food and Beverage | In-kind items and services | $16.49 | General |
| Category: Ophthalmology | ||||||
| 02/12/2024 | Astellas Pharma US Inc | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $2,382.00 | General |
| Category: Ophthalmology | ||||||
| 2024 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 11/29/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Education | Cash or cash equivalent | $17.19 | General |
| Category: Ophthalmology | ||||||
| 2023 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 09/21/2022 | Notal Vision, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $14.54 | General |
| 04/13/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $2,307.30 | General |
| 04/12/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $345.99 | General |
| 2022 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 05/11/2021 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $1,449.40 | General |
| 05/06/2021 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $219.83 | General |
| 2021 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 03/13/2020 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $866.73 | General |
| 2020 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 10/11/2019 | Alimera Sciences, Inc. | Iluvien (Drug) | Food and Beverage | Cash or cash equivalent | $38.86 | General |
| Category: Ophthalmology | ||||||
| 02/21/2019 | US Retina LLC | — | Current or prospective ownership or investment interest | Stock option | $1,137.00 | General |
| 2019 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 09/25/2018 | Alimera Sciences, Inc. | — | Food and Beverage | Cash or cash equivalent | $60.91 | General |
| 09/11/2018 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $19.81 | General |
| Category: UROLOGY | ||||||
| 05/01/2018 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $21.56 | General |
| Category: UROLOGY | ||||||
| 02/27/2018 | Astellas Pharma US Inc | VESICARE (Drug), MYRBETRIQ | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: UROLOGY | ||||||
| 02/15/2018 | Alimera Sciences, Inc. | — | Food and Beverage | Cash or cash equivalent | $111.12 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A randomized, multi-center, single masked, sham controlled, proof-of-concept study of intravitreal CLG561 as a monotherapy and in combination with LFG316 in patients with geographic atrophy (CCLG561X2201A) | Alcon Research Ltd | $30,887 | 24 |
| USER | Alimera Sciences, Inc. | $5,025 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 11,368 | 87,488 | $32.2M | $9.7M |
| 2022 | 24 | 11,376 | 48,700 | $25.3M | $8.9M |
| 2021 | 22 | 11,355 | 48,349 | $29.7M | $9.7M |
| 2020 | 26 | 11,683 | 54,359 | $35.0M | $11.1M |
Total Patients
45,782
Total Services
238,896
Medicare Billing
$39.5M
Procedure Codes
96
All Medicare Procedures & Services
96 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 407 | 4,271 | $8.1M | $2.9M | 36.3% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 344 | 9,108 | $6.3M | $1.7M | 26.6% |
| J3490 | Unclassified drugs | Office | 2023 | 282 | 1,101 | $8.6M | $1.7M | 19.3% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 187 | 45,780 | $3.5M | $1.3M | 38.2% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 289 | 2,772 | $1.5M | $593,873 | 39.4% |
| 67028 | Injection of drug into eye | Office | 2023 | 1,089 | 5,695 | $1.4M | $556,706 | 38.7% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 2,126 | 3,040 | $790,400 | $269,431 | 34.1% |
| 92134 | Imaging of retina | Office | 2023 | 2,450 | 6,504 | $552,840 | $202,731 | 36.7% |
| 92250 | Photography of the retina | Office | 2023 | 2,526 | 6,537 | $673,311 | $191,178 | 28.4% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 73 | 798 | $319,200 | $124,816 | 39.1% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 583 | 685 | $146,590 | $72,673 | 49.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 274 | 274 | $95,352 | $32,627 | 34.2% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 177 | 177 | $54,693 | $18,264 | 33.4% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 200 | 237 | $43,134 | $15,695 | 36.4% |
| 67210 | Destruction of growth of retina using a laser | Office | 2023 | 16 | 22 | $23,980 | $9,123 | 38.0% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 82 | 136 | $14,824 | $4,941 | 33.3% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 58 | 79 | $10,270 | $3,804 | 37.0% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 14 | 14 | $15,554 | $2,668 | 17.2% |
| 92071 | Fitting of contact lens for treatment of eye surface disease | Office | 2023 | 16 | 68 | $5,852 | $2,097 | 35.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 52 | 64 | $3,072 | $1,112 | 36.2% |
| 92020 | Exam of the internal drainage system of eye | Office | 2023 | 46 | 49 | $2,793 | $1,034 | 37.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 23 | 23 | $2,208 | $1,010 | 45.7% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 31 | 31 | $1,643 | $574.78 | 35.0% |
| 76514 | Ultrasound scan of cornea to determine thickness | Office | 2023 | 23 | 23 | $598.00 | $203.32 | 34.0% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 482 | 5,184 | $9.8M | $3.7M | 37.8% |
About Dr. Alexander Eaton, MD
Dr. Alexander Eaton, MD is a Ophthalmology healthcare provider based in Fort Myers, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922021195.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alexander Eaton, MD has received a total of $45,038 in payments from pharmaceutical and medical device companies, with $2,451 received in 2024. These payments were reported across 54 transactions from 6 companies. The most common payment nature is "" ($35,912).
As a Medicare-enrolled provider, Eaton has provided services to 45,782 Medicare beneficiaries, totaling 238,896 services with total Medicare billing of $39.5M. Data is available for 4 years (2020–2023), covering 96 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Fort Myers, FL
- Active Since 07/26/2006
- Last Updated 12/14/2017
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1922021195
Products in Payments
- ILUVIEN (Biological) $5,025
- Izervay (Drug) $2,382
- Foresee Home (Device) $68.64
- MYRBETRIQ (Drug) $41.37
- VESICARE (Drug) $41.07
- Iluvien (Drug) $38.86
- Myrbetriq (Drug) $23.74
- Syfovre (Drug) $17.19
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Fort Myers
Duane Wiggins, M.d, M.D
Ophthalmology — Payments: $271,261
Ophthalmology $271,261
Dr. Stephen Smith, M.d, M.D
Ophthalmology — Payments: $51,062
Ophthalmology $51,062
Jeffrey Robin, M.d, M.D
Ophthalmology — Payments: $17,017
Ophthalmology $17,017
Dr. Michael Collins, M.d, M.D
Ophthalmology — Payments: $16,447
Ophthalmology $16,447
Dr. Ashish Sharma, Md, MD
Ophthalmology — Payments: $12,394
Ophthalmology $12,394
Yasaira Rodriguez-Torres, Md, MD
Ophthalmology — Payments: $10,659
Ophthalmology $10,659